cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Recruiting now · Not applicable

Conditions studied: Locally Advanced Head and Neck Carcinoma

In brief

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment

Key facts

Study ID

NCT07178847

Run by

Centre Jean Perrin

People needed

59

Starts

2025-10-13

Expected to finish

2031-07-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• CH Henri Mondor Aurillac — Aurillac, CANTAL, France (enrolling)
• Centre Jean PERRIN — Clermont-Ferrand, Puy-de-Dôme, France (enrolling)
• Hôpital de la Croix-Rousse — Lyon, France (enrolling)
• CHU de Saint-Étienne — Saint-Etienne, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.